Candela Laser
This article was originally published in The Gray Sheet
Executive Summary
Expects to report a third quarter loss "on significantly lower revenue," according to an April 5 release. The firm cites "the unsettled outlook for health care reform," lower gross margins and the "continuing impact of absorbing the cost of improvements" to its installed base of PLTL-1 lasers, which are being modified because of "reliability problems." The device is used to remove pigmented lesions and tattoos. For the second quarter ended Jan. 2, the firm reported earnings of $24,000 (down 95.7%) on sales of $9.9 mil. (up 16.5%).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.